Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Nail Diseases
Interventions: Suzetrigine, Oxycodone/Acetaminophen, Acetaminophen, Ibuprofen; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alzheimer Disease
Interventions: BMS-708163, BMS-708163 + Ketoconazole, Ketoconazole, Fluconazole, BMS-708163 + Fluconazole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Non Small Cell Lung Cancer, Quality of Life, Coping Skills
Interventions: Supportive Care Mobile Application, Usual Care; Behavioral · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Boston, Massachusetts • Danvers, Massachusetts • Milford, Massachusetts + 2 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo-matched-to-ivacaftor tablet; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Chronic HCV Infection
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 30
States / cities: Phoenix, Arizona • San Diego, California • San Francisco, California + 25 more

Conditions: Cystic Fibrosis
Interventions: VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 25
States / cities: New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more

Conditions: Myocardial Perfusion Imaging, Myocardial Ischemia
Interventions: Ranolazine, Placebo to match ranolazine, SPECT MPI, Exercise; Drug · Procedure · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 26
States / cities: Birmingham, Alabama • Imperial, California • Lincoln, California + 23 more

Conditions: Cancer
Interventions: Dabrafenib, Trametinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 8
States / cities: Little Rock, Arkansas • Santa Monica, California • Bethesda, Maryland + 4 more

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: Ibodutant 10 mg, Placebo; Drug
Lead sponsor: Menarini Group; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 65
States / cities: Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more

Conditions: Solid Tumor
Interventions: Bevacizumab, Cyclophosphamide, Valproic Acid, Temsirolimus; Drug
Lead sponsor: Miller Children's & Women's Hospital Long Beach; Other
Eligibility: 12 Months to 31 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 2
States / cities: Long Beach, California • Orange, California

Conditions: Mild Cognitive Impairment
Interventions: Kodro+, Kodro+D; Other
Lead sponsor: Mt. Sinai Medical Center, Miami; Other
Eligibility: 60 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Miami Beach, Florida

Conditions: Pulmonary Arterial Hypertension
Interventions: RVT-1201, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more

Conditions: Non-ischemic Cardiomyopathy, Systolic Heart Failure (NYHA II-III)
Interventions: Doxycycline, placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 20
States / cities: Dothan, Alabama • Anaheim, California • Imperial, California + 17 more

Conditions: HIV Infections
Interventions: Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL, Topical Non-steroidal anti-inflammatory drug (NSAID), Topical steroid, Topical NSAID placebo, Recombinant human hyaluronidase PH20 (rHuPH20), Topical steroid placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more

Conditions: Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
Interventions: Tagraxofusp, Azacitidine (AZA), Venetoclax; Drug
Lead sponsor: Jacqueline Garcia, MD; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Diabetes Type 2
Interventions: Placebo, Aliskiren; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions: Apixaban 2.5 MG, Placebo oral tablet; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Aging, Insulin Sensitivity, Chronic Disease, Mitochondria, Insulin Resistance
Interventions: Metformin, Placebo oral tablet; Drug
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 40 Years to 75 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Madison, Wisconsin

Conditions: Hepatitis C
Interventions: INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Anaheim, California • La Jolla, California • San Francisco, California + 3 more

Conditions: Disruptive Behavior, Pediatrics
Interventions: Telehealth Parent Child Interaction Therapy, Telehealth Parent Child Interaction Therapy (Delayed Start); Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 2 Years to 7 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Ankylosing Spondylitis
Interventions: Tofacitinib 2 mg, Tofacitinib 5 mg, Tofacitinib 10 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 22
States / cities: Indian Wells, California • Palm Desert, California • Clearwater, Florida + 15 more

Conditions: HCMV Reactivation or HCMV End-Organ Disease
Interventions: 60 mg AIC246, 120 mg AIC246, 240 mg AIC246, Placebo; Drug · Other
Lead sponsor: AiCuris Anti-infective Cures AG; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 11 more

Conditions: Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy, Heart Transplant Failure and Rejection, Post-transplant Lymphoproliferative Disorder, Heart Transplant Infection
Interventions: Everolimus, Tacrolimus, Mycophenolate Mofetil; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more

Search by objective public record fields.

Post-op Analgesia of Nail Unit Procedures

Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole

Supportive Care Mobile Application for Patients With NSCLC

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

Antecedent Metabolic Health and Metformin Aging Study

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Tele-PCIT for Healthy Relationships in Families At-Risk

Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score